Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab in Moderate to Severe Hidradenitis Suppurativa
NCT04242446Phase 3Completed
- Sponsor
- UCB
- Start
- Feb 2020
- Primary completion
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of bimekizumab in hidradenitis suppurativa (HS) (4 arms), sponsored by UCB. Primary endpoint: Hidradenitis Suppurativa Clinical Response 50 at 16 weeks. Started Feb 2020; status: completed.
02
Drugs
bimekizumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT04242446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04242446.